[{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cardior Pharmaceuticals \/ Inkef Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inkef Capital"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1100000000000001,"dosageForm":"Injection","sponsorNew":"Cardior Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Novo Nordisk"}]

Find Clinical Drug Pipeline Developments & Deals by Cardior Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for heart failure.

                          Brand Name : CDR132L

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 25, 2024

                          Lead Product(s) : CDR132L

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Novo Nordisk

                          Deal Size : $1,110.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pat...

                          Brand Name : CDR132L

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          July 20, 2022

                          Lead Product(s) : CDR132L

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.

                          Brand Name : CDR132L

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 25, 2021

                          Lead Product(s) : CDR132L

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inkef Capital

                          Deal Size : $76.0 million

                          Deal Type : Series B Financing

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.

                          Brand Name : CDR132L

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          March 29, 2021

                          Lead Product(s) : CDR132L

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.

                          Brand Name : CDR132L

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 22, 2020

                          Lead Product(s) : CDR132L

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          January 31, 2020

                          Lead Product(s) : CDR132L

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank